Market Overview

UPDATE: Jefferies Raises PT to $23 on Solazyme Post Q3 Beat

Related SZYM
US Stock Futures Edge Lower Ahead Of Home Sales Report
Deutsche Bank Quants Identify Best Stocks To Short

Jefferies reiterated its Buy rating on Solazyme (NASDAQ: SZYM) and raised its price target from $22 to $23.

Jefferies commented, "Q3 was $0.06 better than consensus ($0.05 above our forecast). The current projects remain on track, but the real milestones were Bunge expanding its plans even before Moema starts, a new agreement with ADM, another tailored food oil and a test marketing program for Soladiesel. The focus now shifts to winning downstream partnerships."

Solazyme closed at $7.09 on Wednesday.

Latest Ratings for SZYM

Nov 2014Morgan StanleyDowngradesOverweightEqual-weight
Nov 2014Credit SuisseMaintainsNeutral
Nov 2014Credit SuisseMaintainsNeutral

View More Analyst Ratings for SZYM
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (SZYM)

Around the Web, We're Loving...